| Q35655515 | A novel approach to neural transplantation in Parkinson's disease: use of polymer-encapsulated cell therapy |
| Q48233698 | A single adenovirus vector mediates doxycycline-controlled expression of tyrosine hydroxylase in brain grafts of human neural progenitors |
| Q28830946 | A synopsis on the role of tyrosine hydroxylase in Parkinson's disease |
| Q40718965 | Activation of silenced transgene expression in neural precursor cell lines by inhibitors of histone deacetylation |
| Q52197420 | Adenoviral vector-mediated gene transfer and neurotransplantation: possibilities and limitations in grafting of the fetal rat suprachiasmatic nucleus. |
| Q40489615 | Adenovirus vectors enter the brain |
| Q40957115 | Applications of gene therapy to the CNS. |
| Q34031071 | Approach to ex vivo gene therapy in the treatment of Parkinson's disease |
| Q33939090 | Astrocyte line SVG-TH grafted in a rat model of Parkinson's disease |
| Q44547034 | Behavioral correction of Parkinsonian rats following the transplantation of immortalized fibroblasts genetically modified with TH and GCH genes |
| Q41588794 | Benefits and risks of hosting animal cells in the human brain. |
| Q45883435 | Brain engraftment of autologous macrophages transduced with a lentiviral flap vector: an approach to complement brain dysfunctions |
| Q40278367 | Brain transplantation of human neural stem cells transduced with tyrosine hydroxylase and GTP cyclohydrolase 1 provides functional improvement in animal models of Parkinson disease |
| Q45883914 | Brain transplantation of neural stem cells cotransduced with tyrosine hydroxylase and GTP cyclohydrolase 1 in Parkinsonian rats |
| Q36100649 | Catecholaminergic neurons result from intracerebral implantation of embryonal carcinoma cells |
| Q40779642 | Cells engineered to produce acetylcholine: therapeutic potential for Alzheimer's disease |
| Q28206557 | Cellular replacement therapy for Parkinson's disease--where we are today? |
| Q71889754 | Chromaffin cell xenografts in the rat neocortex can produce antidepressive activity in the forced swimming test |
| Q40495990 | Clinical application of neuronal grafts in Parkinson's disease |
| Q64787878 | Co-grafts of muscle cells and mesencephalic tissue into hemiparkinsonian rats: behavioral and histochemical effects |
| Q40882186 | Conditionally-immortalized astrocytic cell line expresses GAD and secretes GABA under tetracycline regulation |
| Q40918373 | Development of fetal hippocampal grafts in intact and lesioned hippocampus |
| Q64381079 | Dopa-producing astrocytes generated by adenoviral transduction of human tyrosine hydroxylase gene: in vitro study and transplantation to hemiparkinsonian model rats |
| Q41035398 | Dopamine turnover and metabolism in the striatum of parkinsonian rats grafted with genetically-modified human astrocytes |
| Q45877347 | Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts |
| Q40533269 | Dynamics of transgene expression in a neural stem cell line transduced with lentiviral vectors incorporating the cHS4 insulator. |
| Q46659741 | Effects of choline and quiescence on Drosophila choline acetyltransferase expression and acetylcholine production by transduced rat fibroblasts |
| Q42617926 | Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival |
| Q34120723 | Encapsulated neural transplants |
| Q45864156 | GENETICALLY MODIFIED PRIMARY ASTROCYTES AS CELLULAR VEHICLES FOR GENE THERAPY IN THE BRAIN. |
| Q34179305 | Gene delivery and gene therapy with herpes simplex virus-based vectors |
| Q34534274 | Gene therapy for Parkinson's disease |
| Q64382253 | Gene therapy for Parkinson's disease |
| Q34119491 | Gene therapy for Parkinson's disease: review and update |
| Q33837123 | Gene therapy in the CNS. |
| Q34476794 | Gene therapy with herpes simplex virus vectors: progress and prospects for clinical neuroscience |
| Q40952227 | Generation of tyrosine hydroxylase-producing neurons from precursors of the embryonic and adult forebrain |
| Q33693779 | Genetic regulatory elements introduced into neural stem and progenitor cell populations |
| Q36705238 | Genetically modified cells: applications for intracerebral grafting |
| Q64789924 | Herpes simplex virus vectors for gene therapy in Parkinson's disease and other diseases of the nervous system |
| Q33614725 | Human nerual stem cells for brain repair |
| Q35918287 | Human neural stem cells genetically modified for brain repair in neurological disorders |
| Q72534294 | Ibotenic acid lesions of the striatum reduce drug-induced rotation in the 6-hydroxydopamine-lesioned rat |
| Q26829548 | Immortalization of neuronal progenitors using SV40 large T antigen and differentiation towards dopaminergic neurons |
| Q34120728 | Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease |
| Q48529105 | In vivo gene transfer into the adult mammalian central nervous system by continuous injection of plasmid DNA-cationic liposome complex |
| Q45984137 | In vivo production and release of acetylcholine from primary fibroblasts genetically modified to express choline acetyltransferase. |
| Q36928398 | Intracerebral delivery of growth factors: Potential application of genetically modified fibroblasts |
| Q45872237 | Long-term correction of rat model of Parkinson's disease by gene therapy |
| Q52523941 | Long-term histological follow-up of genetically modified myoblasts grafted into the brain. |
| Q45865726 | Long-term phenotypic correction of rodent hemiparkinsonism by gene therapy using genetically modified myoblasts |
| Q41331373 | Long‐term production of neurotrophic factors by astrocyte cultures from hemiparkinsonian rat brain |
| Q35550669 | Metabolic Engineering: Advances in Modeling and Intervention in Health and Disease |
| Q46012400 | Morphological and neurochemical features of cultured primary skin fibroblasts of Fischer 344 rats following striatal implantation |
| Q28290006 | Multipotent neural cell lines can engraft and participate in development of mouse cerebellum |
| Q71796889 | Neural Transplantation |
| Q38079295 | Neural stem cell-based treatment for neurodegenerative diseases |
| Q48316816 | Neurobiology. Better cells for brain repair |
| Q41235622 | Neuronal progenitors as tools for cell replacement in the nervous system |
| Q35165435 | Neurotrophic factors for the investigation and treatment of movement disorders |
| Q48491947 | Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease |
| Q35533275 | Oxidant exposure induces cysteine-rich protein 61 (CCN1) via c-Jun/AP-1 to reduce collagen expression in human dermal fibroblasts |
| Q48672896 | Potential effect of cytokines on transgene expression in primary fibroblasts implanted into the rat brain |
| Q77800528 | Production and functional expression of an epitope-tagged human choline acetyltransferase |
| Q28138668 | Prospects for new restorative and neuroprotective treatments in Parkinson's disease |
| Q34338244 | Recombinant proteins for neurodegenerative diseases: the delivery issue |
| Q40886880 | Reconstitution of a metabolic pathway with triple-cistronic IRES-containing retroviral vectors for correction of tetrahydrobiopterin deficiency |
| Q34120706 | Reconstruction of cortical circuitry |
| Q40368732 | Regulatable acetylcholine-producing fibroblasts enhance cognitive performance |
| Q31045537 | Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer |
| Q36946543 | Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease |
| Q36853737 | Subthalamic hGAD65 gene therapy and striatum TH gene transfer in a Parkinson's disease rat model |
| Q33541810 | Successful survival of grafted transgenic neural plate cells in adult central nervous system environment |
| Q45193147 | Syngeneic central nervous system transplantation of genetically transduced mature, adult astrocytes |
| Q64382865 | The TiPS/TINS Lecture. Catecholamines: from gene regulation to neuropsychiatric disorders |
| Q44010211 | The controlled conversion of human neural progenitor cells derived from foetal ventral mesencephalon into dopaminergic neurons in vitro |
| Q48242730 | Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats |
| Q44515156 | Transplantation to the rat brain of human neural progenitors that were genetically modified using adenoviruses |
| Q38079792 | Trophic factor gene therapy for Parkinson's disease |
| Q28273702 | Tyrosine hydroxylase and Parkinson's disease |
| Q45857411 | Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats. |
| Q32113689 | Viral vectors for gene therapy in Parkinson's disease |
| Q33816851 | Viral vectors in the treatment of Parkinson's disease |
| Q42828777 | beta-Galactosidase transgene expression in transplanted rabbit retinal pigment epithelial cells in vivo |